All In Biotech

Drug Trial Radar · NCT06317662

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

A Phase 2 Study of Blinatumomab in Combination With Chemotherapy for Infants With Newly Diagnosed Acute Lymphoblastic Leukemia With Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 153 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

153

Planned (sponsor's estimate)

Start

Jun 5, 2025

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Sponsor type
NIH
First posted
Mar 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 365 days
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without a KMT2A gene rearrangement (KMT2A-germline \[G\]). Venetoclax is in a class of medications called B-cell lymphoma-2 (Bcl-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Blinatumomab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding venetoclax and/or blinatumomab to standard chemotherapy may be more effective at treating patients with ALL than standard chemotherapy alone, but it may also cause more side effects. This clinical trial evaluates the safety and effectiveness of adding venetoclax and/or blinatumomab to chemotherapy for the treatment of infants with KMT2A-R or KMT2A-G ALL.

Conditions

  • Acute Leukemia of Ambiguous Lineage
  • B Acute Lymphoblastic Leukemia

Interventions

  • Asparaginase Erwinia chrysanthemiDrug

    Given recombinant crisantaspase IM or crisantaspase IM or IV

  • Biospecimen CollectionProcedure

    Undergo collection of blood samples

  • BlinatumomabBiological

    Given IV

  • Bone Marrow AspirationProcedure

    Undergo bone marrow aspiration

  • Calaspargase PegolDrug

    Given IV

  • Computed TomographyProcedure

    Undergo CT

  • CyclophosphamideDrug

    Given IV

  • CytarabineDrug

    Given IT or IV

  • DaunorubicinDrug

    Given IV

  • DexamethasoneDrug

    Given PO or NG or IV

  • DoxorubicinDrug

    Given IV

  • Echocardiography TestProcedure

    Undergo ECHO

  • FDG-Positron Emission TomographyProcedure

    Undergo FDG-PET

  • LeucovorinDrug

    Given PO or NG or IV

  • LevoleucovorinDrug

    Given IV

  • Lumbar PunctureProcedure

    Undergo lumbar puncture

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • MercaptopurineDrug

    Given PO or NG

  • MethotrexateDrug

    Given IT or IV or PO or NG

  • MethylprednisoloneDrug

    Given IV

  • Multigated Acquisition ScanProcedure

    Undergo MUGA

  • PrednisoloneDrug

    Given PO or NG

  • PrednisoneDrug

    Given PO or NG

  • Therapeutic HydrocortisoneDrug

    Given IT

  • ThioguanineDrug

    Given PO or NG

  • VenetoclaxDrug

    Given PO or NG

  • VincristineDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicities (DLTs) (safety phase)Time frame: For the duration of the induction + venetoclax cycle
  2. Incidence of DLTs (expansion phase)Time frame: During the induction, consolidation, and MARMA cycles of Arm B
  3. Minimal residual disease (MRD)-negative remission rateTime frame: At the end of induction

Locations

117 sites in 2 countries. Site status is shown where the registry gives one.

  • Children's Hospital of Alabama

    Birmingham, Alabama · Recruiting

  • Providence Alaska Medical Center

    Anchorage, Alaska · Recruiting

  • Banner Children's at Desert

    Mesa, Arizona · Recruiting

  • Arkansas Children's Hospital

    Little Rock, Arkansas · Recruiting

  • Loma Linda University Medical Center

    Loma Linda, California · Recruiting

  • Miller Children's and Women's Hospital Long Beach

    Long Beach, California · Recruiting

  • UCSF Benioff Children's Hospital Oakland

    Oakland, California · Recruiting

  • Kaiser Permanente-Oakland

    Oakland, California · Recruiting

  • Children's Hospital of Orange County

    Orange, California · Recruiting

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • UCSF Medical Center-Mission Bay

    San Francisco, California · Recruiting

  • Children's Hospital Colorado

    Aurora, Colorado · Recruiting

  • Connecticut Children's Medical Center

    Hartford, Connecticut · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • Alfred I duPont Hospital for Children

    Wilmington, Delaware · Recruiting

  • Children's National Medical Center

    Washington D.C., District of Columbia · Recruiting

  • UF Health Cancer Institute - Gainesville

    Gainesville, Florida · Recruiting

  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital

    Hollywood, Florida · Recruiting

  • Nemours Children's Clinic-Jacksonville

    Jacksonville, Florida · Recruiting

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida · Recruiting

  • AdventHealth Orlando

    Orlando, Florida · Recruiting

  • Arnold Palmer Hospital for Children

    Orlando, Florida · Recruiting

  • Nemours Children's Hospital

    Orlando, Florida · Recruiting

  • Nemours Children's Clinic - Pensacola

    Pensacola, Florida · Recruiting

  • Johns Hopkins All Children's Hospital

    St. Petersburg, Florida · Recruiting

  • Saint Joseph's Hospital/Children's Hospital-Tampa

    Tampa, Florida · Recruiting

  • Saint Mary's Medical Center

    West Palm Beach, Florida · Recruiting

  • Children's Healthcare of Atlanta - Arthur M Blank Hospital

    Atlanta, Georgia · Recruiting

  • Kapiolani Medical Center for Women and Children

    Honolulu, Hawaii · Recruiting

  • Saint Luke's Cancer Institute - Boise

    Boise, Idaho · Recruiting

  • Lurie Children's Hospital-Chicago

    Chicago, Illinois · Recruiting

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois · Recruiting

  • Advocate Children's Hospital-Oak Lawn

    Oak Lawn, Illinois · Recruiting

  • Advocate Children's Hospital-Park Ridge

    Park Ridge, Illinois · Recruiting

  • OSF Children's Hospital of Illinois

    Peoria, Illinois · Recruiting

  • Southern Illinois University School of Medicine

    Springfield, Illinois · Recruiting

  • Riley Hospital for Children

    Indianapolis, Indiana · Recruiting

  • Ascension Saint Vincent Indianapolis Hospital

    Indianapolis, Indiana · Recruiting

  • Blank Children's Hospital

    Des Moines, Iowa · Recruiting

  • University of Kentucky/Markey Cancer Center

    Lexington, Kentucky · Recruiting

Showing 40 of 117 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.